Development and in vivo evaluation of intranasal formulations of parathyroid hormone (1-34)
For efficient intranasal transport of parathyroid hormone (1-34) [PTH(1-34)], there is a great medical need to investigate permeation enhancers for intranasal formulations. In this study, the development of PTH(1-34) intranasal formulations was conducted. Based on conformation and chemical stability...
Main Authors: | Dan Wang, Yimeng Du, Wenpeng Zhang, Xiaolu Han, Hui Zhang, Zengming Wang, Nan Liu, Meng Li, Xiang Gao, Xiaomei Zhuang, Jing Gao, Aiping Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/10717544.2021.1889718 |
Similar Items
-
Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized via Quality by Design Approach
by: Asmaa Saleh, et al.
Published: (2021-05-01) -
Pharmacokinetics of Intranasally Administered Dexmedetomidine in Chinese Children
by: Cheng-Yu Wang, et al.
Published: (2019-07-01) -
Bioavailability of butorphanol after intranasal administration to horses.
by: V. Ferreira, et al.
Published: (2020-12-01) -
Evaluation of Ribavirin–Poloxamer Microparticles for Improved Intranasal Absorption
by: Dipy M. Vasa, et al.
Published: (2021-07-01) -
Enhanced Bioavailability of Tadalafil after Intranasal Administration in Beagle Dogs
by: Jeong-Soo Kim, et al.
Published: (2018-10-01)